临床试验的公共选项？从恢复期血浆中得到的经验教训。

A Public Option for Clinical Trials? Lessons from Convalescent Plasma.

机构信息

NATIONAL CLINICIAN SCHOLARS PROGRAM, DEPARTMENT OF INTERNAL MEDICINE, YALE SCHOOL OF MEDICINE.

SECTION OF GENERAL INTERNAL MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, YALE SCHOOL OF MEDICINE.

出版信息

J Law Med Ethics. 2024;52(1):98-100. doi: 10.1017/jme.2024.57. Epub 2024 May 31.

DOI:10.1017/jme.2024.57

PMID:38818610

Abstract

The case of clinical trials for convalescent plasma during COVID-19 illustrates important lessons for realizing public sector approaches to biomedical research and development. These lessons, centering on mission, transparency, and spillover effects, can be translated to wider efforts to develop a "public option" for clinical trials.

摘要

在 COVID-19 期间，对恢复期血浆临床试验的案例为实现公共部门对生物医学研究和开发的方法提供了重要的经验教训。这些经验教训以使命、透明度和外溢效应为中心，可以转化为更广泛的努力，为临床试验开发“公共选择”。